Context: APOE «2/3/4 genotypes affect plasma lipoprotein(a); however, the effects of APOE genotypes on the prediction of myocardial infarction and aortic valve stenosis by lipoprotein(a) are unknown.
L ipoprotein(a) is a genetic risk factor for atherothrombotic vascular disease (1, 2) with few known natural modulators. Each lipoprotein(a) particle is comprised of one low-density lipoprotein (LDL) particle covalently bound to one molecule of the glycoprotein apolipoprotein(a) by a disulphide bond. Most variation in plasma lipoprotein(a) concentrations is inherited, with smaller isoforms being associated with higher concentrations (3) . Polymorphisms in the number of kringle IV type 2 (KIV-2) repeats and LPA variants rs10455872 and rs3798220, which associate with reduced LPA KIV-2 repeats and increased lipoprotein(a) concentration, have demonstrated that genetically elevated lipoprotein(a) is associated with increased risk of myocardial infarction and calcific aortic valve stenosis (2, 4, 5) .
Gene loci outside the LPA locus can also affect lipoprotein(a) levels, including the APOE «2/3/4 genotype. Human apolipoprotein E has three common isoforms, «2 (Cys112, Cys158), «3 (Cys112, Arg158), and «4 (Arg112, Arg158), which correspond to the «2, «3, and «4 alleles, respectively (6) . In the absence of type III hyperlipidemia, «2 is associated with reduced LDL cholesterol, whereas «4 is associated with increased LDL cholesterol. Although some early studies found no independent relationship between APOE genotype and lipoprotein(a) concentration, most have reported that «2 is associated with lower levels of lipoprotein(a) (7) (8) (9) (10) (11) (12) (13) . However, it is unclear whether the APOE «2/3/4 genotype affects the causal association between elevated lipoprotein(a) and high risk of myocardial infarction and aortic valve stenosis.
We tested the hypothesis that APOE «2/3/4 genotype affects plasma lipoprotein(a), the contribution of plasma apoE levels and LDL cholesterol to this effect, and the associated risk of myocardial infarction and aortic valve stenosis using data from 46,615 individuals in the Copenhagen General Population Study (CGPS).
Materials and Methods

Participants
The CGPS is a study of randomly selected, ethnically homogeneous Danish men and women aged 20 to 100 years reflective of the greater Copenhagen area. It was initiated in 2003 and has ongoing enrolment (14, 15) . At recruitment, patients completed a self-administered questionnaire that was reviewed by an investigator during attendance and underwent a physical examination and blood sampling for biochemical analyses and DNA extraction. We included 46,615 individuals with plasma lipoprotein(a) and plasma apolipoprotein E measurements and with APOE «2/3/4 genotype determination. Of these, 37,582 had LPA KIV-2 repeat number measured and 46,613 had both LPA rs10455872 and rs3798220 variants measured (16) .
For the current study, individuals were followed either from 1977 (start of the national Danish Patient Registry, or date of birth if born after 1 January 1977) or from recruitment until they were censored at the occurrence of death (n = 2588), emigration (n = 124), myocardial infarction (n = 1807 or n = 759), or aortic valve stenosis (n = 345 or n = 207) or until 14 November 2014 (last update of registry), whichever came first; we did not lose track of any individual. Mean follow-up for myocardial infarction was 37 years from 1977 (range: 0.3 to 38 years) or 5 years from recruitment (range: 0 to 10 years); because APOE «2/ 
Plasma measurements
Fresh plasma samples were used to measure total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol (Konelab, Helsinki, Finland). LDL cholesterol was calculated using the Friedewald equation unless plasma triglycerides were greater than 352 mg/dL (4 mmol/L), in which case LDL cholesterol was measured directly. LDL cholesterol was adjusted for lipoprotein(a) cholesterol by two methods, either by subtracting 30% of each individual's lipoprotein(a) total mass from LDL cholesterol, as previously described (17, 18) , or by removing the variation in LDL cholesterol associated with lipoprotein(a) concentrations through regression models. We used the latter correction method, as corrected LDL showed the lowest correlation with lipoprotein(a) with this method.
Lipoprotein(a) total mass was measured, as previously reported, in fresh or recently frozen plasma samples stored at -80°C using one of two validated, commercially available isoform-insensitive immunoturbidometric assays (DiaSys Diagnostic Systems, Holzheim, Germany, or Denka Seiken, Tokyo, Japan) (18) (19) (20) . The DiaSys and Denka Seiken assays were confirmed to be comparable, and we have previously reported that there was no interaction between the assays and their predictive value for disease (16) . All lipoprotein(a) measurements were calibrated to the Denka Seiken assay (19) .
Plasma apolipoprotein E was measured either using nephelometry with a BNII autoanalyzer using goat anti-human apolipoprotein E polyclonal antibodies (OQDLG09; Dade Behring, Deerfield, IL) or turbidimetry with a Kone autoanalyzer (Konelab) using rabbit anti-human apolipoprotein E polyclonal antibodies (A0077; Dako, Glostrup, Denmark). A human serum apolipoprotein E calibrator (apolipoprotein standard serum, OUPGG07; Siemens Health Care Diagnostics, Ballerup, Denmark) was used for both assays. Associations between APOE genotype and levels of apolipoprotein E were similar between the two assays, and individual apolipoprotein E isoforms were detected in plasma with similar sensitivity (21) .
Genotypes
Genotyping of LPA KIV-2 number of repeats was performed using real-time polymerase chain reaction on the ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA) or the CFX384 Real-Time System (Bio-Rad, Copenhagen, Denmark), which yield similar estimates of the sum of repeats on both alleles (15) . The LPA rs10455872 and rs3798220 SNPs were genotyped by TaqMan assays (ABI Prism 7900HT; Applied Biosystems).
For stratified analyses, KIV-2 number of repeats was dichotomized according to the median within each strata of the combination of LPA rs10455872 and rs3798220 SNPs to account for the correlation of the KIV-2 repeat polymorphism with LPA rs10455872 and rs3798220.
APOE genotyping was performed using an ABI PRISM 7900HT Sequence Detection System and TaqMan-based assays (Applied Biosystems). Samples were genotyped for the «4 allele Cys130Arg (rs429358, legacy name Cys112Arg) and the «2 allele Arg176Cys (rs7412, legacy name Arg158Cys). Variation at these two sites defines the six common APOE genotypes («22, «32, «42, «33, «43, and «44). Genotyping for PCSK9 R46L (rs11591147) was by a TaqMan assay (ABI Prism 7900HT; Applied Biosystems) as described (18) .
Other covariables
Body mass index (BMI) was defined as measured weight in kilograms divided by measured height in meters squared. Fully adjusted models also included self-reported use of lipidlowering therapy (statins), because these drugs can reduce apoE blood concentrations (22, 23) . Lp(a) might not be affected by these drugs; however, apolipoprotein E and cardiovascular disease risk can. All other clinical variables were self-reported, dichotomized, and reported in the legend to Table 1 .
Statistical analysis
Stata/S.E. 13.1 (StataCorp LP, College Station, TX) was used for statistical analyses. x 2 tests evaluated Hardy-Weinberg equilibrium, all reported P values were two-sided, and a twosided P value ,0.05 was considered statistically significant. In total, more than 99% of observations were present for the included variables; we imputed the missing data by replacing missing values with the median for that variable when adjusting in regression models; however, results were similar without using imputation.
Quantile regression models were used for estimating median values according to APOE genotypes and reported as median with 95% confidence intervals (CIs). We chose these models because lipoprotein(a) distribution was skewed before and after log transformation and quantile regression may be more robust for data with outliers (24) . Most analyses were adjusted for age and sex only.
Cumulative incidences were estimated using the competing risk proportional subhazard models by the method of Fine and Gray (25) , in which competing risk of death is accounted for. The analyses were adjusted for age and sex. Interactions of plasma lipoprotein(a) with APOE «2/3/4 genotypes on outcomes were tested using a Wald test. Cox proportional hazards regression was used to estimate hazard ratios with 95% CI for Continuous variables summarized as median and interquartile range.
Abbreviations: eGFR, estimated glomerular filtration rate. a P calculated using Cuzick nonparametric trend test.
b Women with menopause receiving hormone replacement therapy.
c Premenopausal women only.
incident myocardial infarction or aortic valve stenosis. We used age as the time scale with delayed entry (left truncation). Thus, age differences were automatically adjusted for and referred to in text, tables, and figures as age adjusted. Additional adjustments are clearly marked in the text. The proportional hazards assumption was assessed in Cox regression models graphically by plotting -ln[-ln (survival)] vs ln(analysis time); we detected no major violations of the proportional hazards assumption.
Results
In 46,615 adults from the general population with both lipoprotein(a) measurements and APOE genotype, the frequencies were 2.9% for «44, 25.6% for «34, 55.6% for «33, 12.4% for «23, 2.9% for «24, and 0.7% for «22; these genotype distributions did not differ from the Hardy-Weinberg equilibrium (P = 0.36 for Cys130Arg and P = 0.67 for Arg176Cys used to define the « genotypes). APOE genotypes differed in relation to age, BMI, alcohol consumption, C-reactive protein, alanine transaminase (ALT), thyroid-stimulating hormone (TSH), and the use of lipid-lowering medication; however, the differences in ALT and TSH were minor (Table 1) . Diabetes, menopausal status, hormone replacement use, renal function, and aspirin use did not differ between APOE genotypes.
Plasma lipoprotein(a)
Using «33 as reference, unadjusted analysis showed a clear, graded effect of the «2 allele upon plasma lipoprotein(a) concentration (Supplemental Fig. 1 ). Subjects with «22 had 36% lower median lipoprotein(a) concentration than «33 subjects (P = 8 3 10
-21
). Subjects with «24 and «23 also demonstrated reduced lipoprotein(a) concentrations compared with «33 subjects, indicating a stepwise effect relating to «2 status. Unexpectedly, «44 subjects had lower lipoprotein(a) levels than «33 subjects. APOE «24 heterozygotes also had lower levels than «23 heterozygotes, suggesting a stepwise effect related to «4 carrier status.
The distributions of lipoprotein classes and plasma apolipoprotein E concentrations were analyzed according to APOE polymorphism and correspond to a previous report on the combined CGPS and Copenhagen City Heart Study cohorts (21) (Supplemental Fig. 2 ). In brief, subjects with «2 and «4 alleles had higher plasma triglycerides than «33 homozygotes, and this was most marked for «22 homozygotes. There were modest effects of APOE genotype on plasma HDL cholesterol, with «23 heterozygotes having slightly higher HDL and «43 allele carriers having slightly lower HDL than «33 homozygotes. Median LDL cholesterol was much lower in «22 homozygotes than in «33 homozygotes (38%, P = 2 3
-64
) and higher in «44 homozygotes than in «33 homozygotes (8%, P = 7 3 10 -16 ). Heterozygotes for the «2
and «4 alleles showed similar trends. Median plasma apolipoprotein E was higher in «2 carriers and lower in «4 carriers than in «33 homozygotes. In «22 homozygotes, plasma apolipoprotein E was more than double that of «33 homozygotes (P , 1 3 10 -273 ).
Compared with «33 individuals, age-and sex-adjusted lipoprotein(a) concentrations were lower by 9% in those with «44, 1% (P . 0.05) in «34, 15% in «23, 24% in «24, and 36% in «22; after further adjustment for plasma apolipoprotein E, corresponding values were 4% (P . 0.05), 1% (P . 0.05), 22%, 28%, and 62% lower, respectively (Fig. 1, left panels) . However, further adjustment for LDL cholesterol, triglycerides, HDL cholesterol, and all statistically significant variables in Table 1 only had a minor influence (Fig. 1, right  panels) . After multivariable adjustment, «22 subjects had 67% lower lipoprotein(a) concentrations than «33 (P = 1 3 10 -62 ).
Importance of LPA genotype
The cumulative distribution of lipoprotein(a) concentrations between «2 allele carriers and «33 subjects differed markedly, but there was no effect of APOE genotype on the distribution of KIV-2 repeats (Supplemental Fig. 3 ).
As expected, subjects with smaller apolipoprotein(a) isoforms (fewer KIV-2 repeats, or LPA rs10455872 or LPA rs3798220 carrier status) had higher lipoprotein(a) concentrations than those with larger apolipoprotein(a) isoforms (Fig. 2) . Lipoprotein(a) concentrations decreased according to «2 allele status in a stepwise manner for all stratifications. There was no interaction between the number of KIV-2 repeats and the effect of APOE genotype on lipoprotein(a) concentrations (P = 0.12) and, at most, a weak interaction between LPA variant carrier status and the effect of APOE genotype on lipoprotein(a) concentrations (P = 0.02).
Importance of LDL cholesterol reduction
In «22 subjects, the median age and sex adjusted lipoprotein(a) and LDL cholesterol were, respectively, 35% (P = 8 3 10 ) and 38% (P = 7 3 10 -60
) lower than in «2 noncarriers (Fig. 3) . In «2 heterozygotes, lipoprotein(a) and LDL were, respectively, 14% (P = 3 3 10 -17
) and 16% (P = 2 3 10 -270 ) lower than in «2 noncarriers, indicating a similar and proportional reduction in lipoprotein(a) and LDL cholesterol according to «2 carrier status. For comparison, in PCSK9 rs11591147 loss-offunction carriers, the median lipoprotein(a) and LDL cholesterol concentrations were, respectively, 7% (P = 0.05) and 12% (P = 5 3 10 -28 ) lower than in noncarriers. The effect of PCSK9 rs11591147 carrier status on lipoprotein(a) concentrations was of borderline significance and less than that observed with «2 heterozygotes despite similar proportional reduction in LDL cholesterol.
Myocardial infarction and aortic valve stenosis
Compared with «2 carriers with lipoprotein(a) #50 mg/dL, the hazard ratio for myocardial infarction was 1.26 (95% CI: 1.06 to 1.49) for «2 noncarriers with lipoprotein(a) #50 mg/dL, 1.68 (1.21 to 2.32) for «2 carriers with lipoprotein(a) .50 mg/dL, and 1.92 (1.59 to 2.32) for «2 noncarriers with lipoprotein(a) .50 mg/dL (interaction, P = 0.57); corresponding values for aortic valve stenosis were 1.05 (0.74 to 1.51), 1.49 (0.72 to 3.08), and 2.04 (1.46 to 2.26), respectively (interaction, P = 0.50) (Fig. 4) . Results were similar when endpoints only accumulated after the day of recruitment were used (Supplemental Fig. 4 ).
Additional analyses were carried out by percentiles of lipoprotein(a) concentration to investigate whether part of the effect of lipoprotein(a) concentration on myocardial infarction and aortic valve stenosis may represent the effect of APOE genotype (Fig. 5 ). There was a clear graded relationship between percentiles of lipoprotein(a) concentration and the incidence of myocardial infarction (trend, P = 1 3 10
) and aortic valve stenosis (trend, P = 4 3 10 -6 ) after adjusting for age and sex, which was unaffected by further adjusting for APOE genotype.
Results were similar when endpoints were only accumulated after the day of recruitment (Supplemental Fig. 5 ). Lastly, as lipoprotein(a) concentrations may be related to a diagnosis of familial hypercholesterolemia (18), we performed a subgroup analysis of those with LDL cholesterol .4.9 mmol/L (i.e., concentrations compatible with familial hypercholesterolemia). The results for cumulative incidence of myocardial infarction were similar to those presented in Fig. 4 (Supplemental Fig. 6 ), although with greatly reduced power, as only 2411 individuals remained in the analysis.
Discussion
The current study establishes that although APOE «2 is a strong genetic determinant of low lipoprotein(a) concentrations, it does not modify the causal association of lipoprotein(a) with myocardial infarction or aortic valve stenosis. This is a unique finding. The «2 allele decreases circulating lipoprotein(a) concentration independently of other lipoprotein concentrations, plasma concentration of apolipoprotein E, and apolipoprotein(a) size polymorphism. In contrast, the «4 Figure 2 . Apolipoprotein(a) isoform size and «2 allele and median plasma lipoprotein(a) concentration. Lipoprotein(a) concentrations in 46,613 Danish adults from the CGPS according to APOE «2 carrier status, adjusted for age and sex and stratified according to size of apolipoprotein(a) isoform (kringle IV type number of repeats) and LPA variants rs10455872 and rs3798220. P values for «22 homozygotes and «23 and «24 heterozygotes were derived using a quantile regression model. D indicates percent differences in median concentrations for «22 and for «23 and «24 heterozygotes compared with the «44, «34, and «33 subjects. P = 0.12 for interaction between KIV-2 number of repeats and effect of «2, and P = 0.02 for interaction between LPA variants and effect of «2. Figure 3 . Genetic variation in LDL cholesterol and lipoprotein(a) concentration. The effects of APOE «22 and «2 heterozygosity («23+«24) relative to noncarriers of «2 («33+«34+«44) and of PCSK9 rs11591147 loss-of-function mutation relative to PCSK9 rs11591147 noncarriers on lipoprotein(a) (top) and LDL (bottom) concentrations. P values were derived using quantile regression adjusted for age and sex. D indicates percent difference in median concentration compared with the noncarriers of «2 or PCSK9 rs11591147 noncarrier as appropriate.
had minimal effects on lipoprotein(a) concentrations compared with the «3 allele.
The potential for genes outside the LPA locus to regulate lipoprotein(a) concentrations is relatively unexplored. Familial hypercholesterolemia is associated with elevated lipoprotein(a); lipoprotein lipase deficiency, abetalipoproteinemia, and lecithin cholesterol acyl transferase activity deficiency are associated with low levels of lipoprotein(a) (1); and a recent genome-wide association study identified mutations in the APOE locus as modulating lipoprotein(a) concentration (26) . In our study, after adjusting for laboratory and clinical covariables, «22 subjects had a 67% lower lipoprotein(a) concentration than «33 subjects. To the best of our knowledge, this represents the largest reduction of lipoprotein(a) levels achieved by any gene outside the LPA locus reported to date and both supports and extends the findings of previous studies (7) (8) (9) (10) (11) 13) .
Adjustment for clinical differences between APOE genotypes such as age, BMI, alcohol consumption, and Figure 4 . Cumulative incidence of myocardial infarction and aortic valve stenosis stratified by concentrations of lipoprotein(a) and «2 allele carrier status. The cumulative incidence of myocardial infarction (top) and aortic valve stenosis (bottom) in up to 46,615 Danish adults from the CGPS were stratified by the concentration of lipoprotein(a) #50 mg/dL or .50 mg/dL and the presence or absence of the «2 allele. Hazard ratios are expressed relative to subjects who were both lipoprotein(a) #50 mg/dL and carriers of the «2 allele. P values refer to interaction between «2 allele status and lipoprotein(a) in predicting myocardial infarction and aortic valve stenosis. E, number of events; HR, hazard ratio calculated by Cox regression analysis; N, number of individuals.
the use of lipid-lowering medication did not change the effect of «2 on lipoprotein(a) concentration. Inflammation, thyroid disease, liver disease, renal disease, diabetes, menopausal status, and aspirin use have been variably associated with variations in lipoprotein(a), and C-reactive protein, ALT, and TSH did show statistical variation with APOE genotype, but adjustment for these parameters did not affect the association with lipoprotein(a) concentration.
APOE «2 carriers had lower LDL cholesterol than «33 subjects (6, 13) , and the reduction of lipoprotein(a) in «2 carriers in the present and previous studies was proportional to the reduction of LDL cholesterol (7, 8, 10) . In contrast, the effect of PCSK9 rs11591147 on lipoprotein(a) concentrations was of borderline significance and less than that of «2 heterozygotes, despite similar proportional reduction in LDL cholesterol. After multivariable adjustment incorporating lipoprotein concentrations, «2 carriers still had decreased lipoprotein(a) concentrations relative to «33. Thus, although the effects of «2 on lipoprotein(a) could be partially explained by its effects on LDL cholesterol, additional mechanisms are likely to operate.
This study reports that the effect of «2 on lipoprotein(a) levels is independent of plasma apolipoprotein E concentration. Apolipoprotein E levels were higher in «2 carriers, as previously reported (12, 21) , and this may explain a recent report that plasma apolipoprotein E and lipoprotein(a) concentrations were inversely correlated (27) . Unexpectedly, adjustment for plasma apolipoprotein E levels strengthened the association between APOE polymorphism and lipoprotein(a) concentration. Increasing plasma apolipoprotein E is associated with hyperlipidemia (27) (28) (29) via inhibition of LDL clearance, enhanced production of apoB-containing lipoproteins, and inhibition of lipoprotein lipase-mediated lipolysis (6).
It is likely that the hyperlipidemic effects of increasing plasma apolipoprotein E, which are not isoform specific (6) , compete with the isoform-specific lowering of lipoprotein(a) mediated by «2.
Our study differs from a recent large cohort in identifying that «44 is associated with lower unadjusted lipoprotein(a) concentration than «33 (13). Our findings appear robust, as lipoprotein(a) concentrations were also lower in «24 than «23 heterozygotes. Furthermore, the claim that «44 had lower levels than «33 in the previously mentioned study was largely based on estimation of the mean concentrations of lipoprotein(a), whereas the differences were comparable to ours for median levels of lipoprotein(a) in the same study. Thus, differences between studies could be due to differences in populations (clinic based vs general population), ethnicity (mixed vs white Danes in our study), adjustments in the analyses (e.g., we had information on comorbidities, apoE concentration, and lipid-lowering therapy), and differences in statistical modeling (mean vs median). Both «44 and «22 subjects in our study had higher triglycerides than «33, as previously reported by others (12) . However, «4 and «2 remained associated with lower lipoprotein(a) after adjustment for all lipoproteins, suggesting this is not a likely explanation. Our group has previously shown that «4 is associated with lower apoE levels than «3 and «2 (21) . The association between «4 and lower lipoprotein(a) was diminished after adjustment for apoE concentrations, indicating that low plasma apoE concentrations could contribute to the effect of the «4 isoform. This is unlike the case for «2, which has higher plasma apoE levels.
The mechanism by which «2 reduces lipoprotein(a) concentration requires formal investigation. We propose that the effects are achieved posttranslationally by the combined effects of reducing LDL concentration, interfering with lipoprotein(a) assembly, and promoting lipoprotein (a) clearance. Most variation in lipoprotein(a) concentrations is attributable to differences in production (30) . Apolipoprotein(a) secretion efficiency improves in the presence of lipoprotein-containing serum (31) , possibly related to enhanced lipoprotein(a) assembly on the hepatocyte surface (32) . Whether apolipoprotein E2 impairs lipoprotein(a) assembly because of impaired binding to the LDL receptor, LDL receptor-related protein (LRP-1), or heparan sulfate proteoglycans or modulates apolipoprotein(a) recycling via the plasminogen receptor (33) is unknown.
Analysis according to carrier status for LPA variants rs10455872 and rs3798220 or polymorphism of KIV-2 demonstrated that «2 decreases lipoprotein(a) concentration independently of apolipoprotein(a) size polymorphism. In one previous study, only apolipoprotein(a) isoform S2 was lower in presence of «2, with no overall effect of «2 on Lp(a) levels (34) , and in another, there were ethnic differences in the apparent strength of the association (11) , which could relate to differences in isoform distribution. The large size of our study and the use of two independent genetic instruments ensures our findings are robust within this ethnically homogenous Danish population. However, it remains possible that a stronger effect of «2 could be seen in other populations and that alternative approaches to determining KIV-2 genotypes that do not summate the two alleles may provide further insights (35) . Our results imply that the effect of «2 will be broadly relevant to most populations, regardless of variations in isoform size, and may have important population health implications for risk stratification.
APOE polymorphism has been previously associated with cardiovascular outcomes (12, 36) . Although «2 reduced lipoprotein(a) levels, it did not modify the risk of myocardial infarction nor the risk of aortic valve stenosis after subjects were stratified for lipoprotein(a) concentrations. These findings suggest that lipoprotein(a) levels may be a determinant of the apparent protective effect of «2 in cardiovascular disease. Future attribution of cardiovascular risk to «2 will need to re-evaluate the contribution of lipoprotein(a) to such risk stratification.
The effect of «2 may be greater in African Americans than in whites (11) , and our data in ethnically homogenous Danes may underestimate the potential effect size of the «2 allele on lipoprotein(a) levels in other ethnicities. Although we did not directly measure isoform size in our population, we could not find an isoform-specific effect of the «2 allele using LPA KIV-2 number of repeats or rs10455872 or rs3798220 carrier status as genetic instruments.
APOE «2 is a strong genetic determinant of low lipoprotein(a) concentrations but does not modify the causal association of lipoprotein(a) with myocardial infarction or aortic valve stenosis. Studies evaluating APOE «2/3/4 genotype and cardiovascular outcomes should concurrently consider lipoprotein(a) levels, and mechanistic studies should identify the pathways by which «2 decreases lipoprotein(a).
